The short version of GHK-Cu fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
| Property | Value | Notes |
|---|---|---|
| Copper binding sites | Imidazole, amino, and amide nitrogens | Form chelate rings with Cu(II) |
| Conditional binding constant | Reported near 10^16 at neutral pH | Value depends on method and medium |
| Visible absorption | Broad band in the blue-violet region | Source of the characteristic color |
| Common analytical methods | LC-MS, HPLC, UV-Vis, ICP-OES | Used for identity and copper content |
| Main degradation routes | Oxidation, photolysis, hydrolysis | Accelerated by light, heat, and pH extremes |
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
The acetic acid bacteria in kombucha are aerobic, meaning that they require oxygen for their growth and activity. Hence, the bacteria initially migrate and assemble at the air interface, followed by the excretion of bacterial cellulose after about 2 days. The mixed, presumably mutualistic culture has been further described as being lichenous, in accord with the reported presence of the known lichenous natural product usnic acid, though as of 2015, no report appears indicating the standard cyanobacterial species of lichens in association with kombucha fungal components.
Protein DHX8 is part of a protein complex called spliceosome, which is in charge of pre-mRNA splicing. The spliceosome has eight major functional states, each with distinct composition and structure; five of the eight states have been structurally characterized. DHX8 have different domains: a S1 RNA binding domain (DEAD/DEAH box), an helicase conserved C-terminal domain, helicase associated domain (HA2), and an oligonucleotide/oligosaccharide-binding (OB)-fold, each joined by intrinsically disordered regions. There are some regions of the protein which are very important for its activity, like R620 and the hook-loop and hook-turn regions. Also, DHX8Δ547 is the catalytically active core of the protein DHX8. It is made of two RecA domains and the C-terminal WH, ratchet-like and OB-fold domains and the N-terminal region. The total weight of the DHX8 structure is 156580.13 Da. Secondary structure:
== Enhanced chemiluminescence == Enhanced chemiluminescence (ECL) is a common technique for a variety of detection assays in biology. A horseradish peroxidase enzyme (HRP) is tethered to an antibody that specifically recognizes the molecule of interest. This enzyme complex then catalyzes the conversion of the enhanced chemiluminescent substrate into a sensitized reagent in the vicinity of the molecule of interest, which on further oxidation by hydrogen peroxide, produces a triplet (excited) carbonyl, which emits light when it decays to the singlet carbonyl. Enhanced chemiluminescence allows detection of minute quantities of a biomolecule. Proteins can be detected down to femtomole quantities, well below the detection limit for most assay systems.
Lately First UK Offshore Wind Champion and Chair, Offshore Wind Acceleration Taskforce. For services to Offshore Wind Energy. Ruth Beatrice Pitter. Member, Anchor Society and Member, Stand Against Racism and Inequality. For services to Equality, to Charity and to the community in Bristol. Andrew Geoffrey Pollock. Founder, CLEVR Money. For services to Financial Inclusion. Phillip George Potter. Regional Lead, West Midlands, Wales and South West, UK Export Finance. For services to Business and to the community in Worcestershire. Jeffrey Richard Powell. Sports Writer and Columnist, Daily Mail. For services to Journalism and to Sport. Patricia Mary Pritchard. For services to Childcare and Early Years. Dr. Heidi Probst. Researcher, Lecturer and lately Director, Health Research Institute, Sheffield Hallam University. For services to Radiography. Howard John Provis. For services to the Welsh Blood Transfusion Service and to the community in Barry and the Vale of Glamorgan. Brian Thomas James Purcell. Lately Northern District Manager, St John Ambulance. For voluntary service in Northern Ireland. Anthony Martin Quinn. Lately Business Development Director, Co-operation Ireland. For services to Community Relations in Northern Ireland. Jayshree Rajkotia. Trustee and Vice Chair, Bharatiya Vidhya Bhavan, Institute of Indian Art and Culture. For services to Indian Culture. Melinda Elizabeth Raker, DL. Founder and Patron, The YANA Charity. For services to Rural Mental Health and Wellbeing. Laura-Jane Rawlings. Chief Executive Officer, Youth Employment UK. For services to Young People.
Clinical pathologists may assist physicians in interpreting complex tests such as platelet aggregometry, hemoglobin or serum protein electrophoresis, or coagulation profiles. If interfering substances are suspected, they may recommend alternate test methods. For example, hemolysis, icterus, lipemia, or heterophile antibodies may confound results obtained by traditional methods such as ion-selective electrodes, enzymatic assays or immunoassays. Alternate methods such as blood gas analysers, point-of-care testing or mass spectrometry may help resolve the clinical question.
Sources: en.wikipedia.org
Before the advent of SPPS, solution methods for chemical peptide synthesis relied on tert-butyloxycarbonyl (abbreviated 'Boc') as a temporary N-terminal α-amino protecting group. The Boc group is removed with acid, such as trifluoroacetic acid (TFA). This forms a positively charged amino group in the presence of excess TFA (note that the amino group is not protonated in the image on the right), which is neutralized and coupled to the incoming activated amino acid. Neutralization can either occur prior to coupling or in situ during the basic coupling reaction. The Boc/Bzl approach retains its usefulness in reducing peptide aggregation during synthesis. In addition, Boc/benzyl SPPS may be preferred over the Fmoc/tert-butyl approach when synthesizing peptides containing base-sensitive moieties (such as depsipeptides or thioester moeities), as treatment with base is required during the Fmoc deprotection step (see below). Permanent side-chain protecting groups used during Boc/benzyl SPPS are typically benzyl or benzyl-based groups. Final removal of the peptide from the solid support occurs simultaneously with side chain deprotection using anhydrous hydrogen fluoride via hydrolytic cleavage. The final product is a fluoride salt which is relatively easy to solubilize. Scavengers such as cresol must be added to the HF in order to prevent reactive cations from generating undesired byproducts.
=== Headache === Doxepin is under development by Winston Pharmaceuticals in an intranasal formulation for the treatment of headache. As of August 2015, it is in phase II clinical trials for this indication.
=== Impeachment of Sara Duterte === In December 2024, Duterte offered to join the defense team of his daughter, Vice President Sara Duterte, against her impeachment. On February 18, 2025, two weeks after the vice president was impeached by the House of Representatives, Duterte was listed as the legal counsel of his daughter in her Supreme Court petition to stop the impeachment from proceeding to trial.
==== Information laundering ==== Generative AI has been noted for its use by state-sponsored propaganda campaigns in information laundering. According to a 2025 report by Graphika, generative AI is used to launder articles from Chinese state media such as China Global Television Network through various social media sites in an attempt to disguise the articles' origin.
=== Glutamate transport === Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline's ability to decrease levels of glutamate in the brain. This is in part due to an indirect decrease in the extrasynaptic NMDA-TRMP4 death signaling pathway. It's important to also note it is only the extrasynaptic NMDA receptors responsible for excitotoxicity.
Sources: en.wikipedia.org
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.
Reversed-phase high-performance liquid chromatography and mass spectrometry are common for the peptide portion. Copper content is usually determined by inductively coupled plasma techniques or by spectrophotometry. Ultraviolet-visible spectroscopy takes advantage of the visible absorption band of the copper complex.
Light, oxygen, and elevated temperature promote degradation of the peptide, and strongly acidic or alkaline conditions accelerate hydrolysis. The copper complex is generally more resistant to oxidation than the free peptide. Storage in a dry, dark, cold environment limits loss over time.
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.